Oncolytics Biotech Highlights Strong Pelareorep Data in Colorectal Cancer

Oncolytics Biotech ( (ONCY) ) just unveiled an announcement.

On May 4, 2026, Oncolytics Biotech reported new data from its REO 022 study showing that pelareorep-based combination therapy produced a 19.5-month median duration of response in second-line KRAS-mutant, microsatellite-stable metastatic colorectal cancer, roughly tripling to quadrupling historical 4–6 month benchmarks. The regimen of pelareorep with bevacizumab and FOLFIRI achieved a 33% objective response rate versus 6–11% for standard of care, and the company is enrolling a randomized Phase 2 trial in the same population while engaging with the U.S. Food and Drug Administration to explore a potential accelerated approval pathway, underscoring pelareorep’s potential to address a high-need segment of the large colorectal cancer market and potentially strengthen Oncolytics’ position in gastrointestinal oncology.

The durability and magnitude of responses reported in RAS-mutant MSS metastatic colorectal cancer, a population with typically rapid progression and limited treatment durability, suggest pelareorep-based combinations could meaningfully extend clinical benefit and differentiate the company’s platform within the crowded oncology space. Positive regulatory dialogue and successful Phase 2 outcomes could materially influence Oncolytics’ development trajectory, partnering prospects, and future commercial positioning in gastrointestinal cancers, particularly if pelareorep becomes a viable second-line option for this hard-to-treat cohort.

The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.

Spark’s Take on ONCY Stock

According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.

The score is held back primarily by weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Offsetting this are constructive corporate/regulatory developments (Fast Track and FDA alignment) and a modestly improved near-term technical picture, while valuation support is limited by negative earnings and no dividend data.

To see Spark’s full report on ONCY stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic designed to convert immunologically cold tumors hot by activating innate and adaptive immune responses. The company is focused on metastatic gastrointestinal and other solid tumors, advancing pelareorep in combination with chemotherapy and checkpoint inhibitors and holds U.S. Fast Track designations in colorectal and pancreatic cancers. Oncolytics has reported encouraging data in first-line pancreatic cancer, metastatic breast cancer, and early-phase anal and colorectal cancer studies, and is seeking strategic partnerships to accelerate development and commercialization.

Average Trading Volume: 1,244,036

Technical Sentiment Signal: Sell

Current Market Cap: $101M

Find detailed analytics on ONCY stock on TipRanks’ Stock Analysis page.